Objective Some angiotensin receptor blockers (ARBs), including irbesartan, increase the peroxisome proliferator-activated receptor (PPAR)-g activity in vitro. The aim of this study was to evaluate the interactions between obesity and the effects of irbesartan on inflammatory cytokines in chronic glomerulonephritis patients without diabetes. Methods The anti-inflammatory effects of irbesartan were evaluated in 29 hypertensive chronic glomerulonephritis patients without diabetes in a prospective, single-arm study. Results Following treatment with irbesartan for 26 weeks, blood pressure and proteinuria significantly decreased, as previously reported (blood pressure decreased from 142±1/87±1 to 131±1/81±1 mmHg and the urine protein/creatinine ratio decreased from 1,030±143 to 779±121 mg/g Cr). BMI did not significantly change after the study. Among the inflammatory parameters, the concentrations of adiponectin and highsensitivity C-reactive protein (hsCRP) significantly improved after treatment; however, the changes in the concentrations of interleukin-6 (IL-6), tumor necrosis factor (TNF)-a and leptin did not reach statistical significance. Moreover, the changes in these five parameters following treatment were moderately correlated with the BMI values obtained at the initiation of the study, and the improvements were particularly prominent in those with a BMI greater than 25. Improvements in proteinuria were significantly correlated with increases in the adiponectin concentration, but not with BMI. There was also a moderate correlation between the changes in the adiponectin and insulin concentrations. Conclusion Irbesartan improves metabolic parameters in nondiabetic hypertensive chronic glomerulonephritis patients, especially those with a high BMI. Improving the adiponectin concentration may be important for reducing proteinuria.
Introduction
Angiotensin receptor blockers (ARBs) are widely used for the treatment of hypertension, especially in patients with proteinuria, due to their renoprotective effects (1) . According to the guidelines for treating hypertension in patients with proteinuria issued by the Japanese Society of Hypertension, ARBs are recommended as first-line drugs (2) . The target blood pressure for treatment in these patients is 130/80 mmHg, and a stricter target blood pressure of 125/75 mmHg is recommended if the urinary protein level is greater than 0.5 g/day (2) . Irbesartan, an ARB, is reported to exert renoprotective effects (3) . It has also been reported that some ARBs alter peroxisome proliferator-activated receptor (PPAR) agonistic actions and improve the expression of inflammatory cytokines in vitro (4) . Furthermore, the beneficial effects of these drugs in clinical situations have also been reported (5) . Improving PPAR gamma activity is beneficial, especially in patients with metabolic syndrome and diabetes; however, there have been only a few such reports of patients without diabetes. It has also been reported that obesity is a risk factor for proteinuria (6) , and such disease is sometimes called obesity-related glomerulopathy (7) . Therefore, treatment with ARBs exerting PPAR agonistic effects might be beneficial, especially in obese proteinuric patients. In addition, the involvement of adiponectin in proteinuria has been reported (8) .
The purpose of this study was to evaluate the interactions between obesity and the effects of irbesartan on inflammatory cytokines in hypertensive patients with chronic glomerulonephritis. Because diabetes worsens the inflammatory cytokine levels, we evaluated patients without diabetes. We also analyzed whether the effects of the drug differ depending on the BMI. Because adiponectin has been reported to be important in podocyte injury, we further evaluated the relationship between adiponectin and proteinuria.
Materials and Methods

Study design
This is a prospective, single-center, single-arm study. This study consisted of a 4-week drug titration period and a 22-week treatment period. The trial was performed in compliance with the Declaration of Helsinki. The ethical committee of the University of Tsukuba Hospital (Tsukuba, Ibaraki, Japan) approved the protocol and written informed consent was obtained from all patients before enrollment. This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as UMIN000006609.
Patient entry
Adult Japanese patients referred to the Department of Nephrology at the University of Tsukuba Hospital (Tsukuba, Ibaraki, Japan) for evaluation of mild to moderate hypertension with moderate proteinuria and diagnosed with chronic glomerulonephritis were included in this study. Patients with blood pressure values greater than 180/100 mmHg or less than 130/80 mmHg at the clinic were excluded. Patients were excluded if they had massive proteinuria (a urinary protein/creatinine ratio greater than 3.5 g/g creatinine) or diabetes (an HbA1C level determined by the Japanese Diabetes Society method to be more than 5.8% or present usage of anti-diabetic drugs). Patients with clinically active cancer or apparent inflammation (such as acute infections or chronic inflammatory disorders) were also excluded. Patients who had been prescribed RAS inhibitors (e.g., ARBs, ACE inhibitors, spironolactone and direct renin inhibitors), glucocorticoids or immune suppressants (such as cyclosporine and corticosteroids) within the previous two months were also excluded. The administration of other anti-hypertensive drugs (such as amlodipine as a Ca-channel blocker, diuretics, a-blockers and b-blockers) was continued during the study if the dose was not changed. Drugs that can affect metabolic parameters, such as anti-dyslipidemic drugs, were also continued if the dose was not changed during the study.
Dosing schedule
After obtaining written informed consent, irbesartan was initiated at a dose of 100 mg and titration was performed up to 200 mg during the first four weeks. The target blood pressure was 130/80 mmHg in the patients with urinary protein/creatinine ratios less than 0.5 g/g creatinine and 125/75 mmHg in those with urinary protein/creatinine ratios greater than 0.5 g/g creatinine. The highest dose of irbesartan was continued until the end of the study. Titration was terminated if hypotension or a blood pressure of 120/70 mmHg was recorded. On the other hand, if the blood pressure was greater than 140/90 mmHg four weeks after the initiation of the study, addition (or increased dosage) of a Ca-channel blocker (such as amlodipine) was permitted and attempts were made to maintain the target level of blood pressure.
Blood pressure monitoring and sampling of blood and urine
Blood pressure and body weight were measured at zero, four and 26 weeks after the initiation of the study. Blood and spot urine sampling was performed at zero, four and 26 weeks after the initiation of the study. For the blood specimens, parameters related to inflammation (hsCRP, TNF-a, adiponectin, leptin, IL-6 and insulin) as well as the levels of blood urea nitrogen (BUN), creatinine, potassium, LDLcholesterol, HDL-cholesterol and fasting blood glucose were measured using the samples. For the urine specimens, the protein and creatinine concentrations were measured, and the urine protein/creatinine ratio was calculated. The BUN, creatinine, potassium, LDL-cholesterol and HDL-cholesterol concentrations were measured using an autoanalyzer. The hsCRP, adiponectin and leptin concentrations were measured with microparticle-enhanced turbidimetric assays (9), latex particle-enhanced turbidimetric immunoassays (10) and enzyme-linked immunosorbent assay (ELISA) (11), respectively. The TNF-a, insulin and IL-6 concentrations were measured using ELISA kits (TiterZime EIA kit, Assay Inc., Ann Arbor, USA) (12) .
Endpoints
The primary endpoints of this study were to evaluate changes in these physical and blood/urine parameters after treatment with the drug for 26 weeks. The secondary endpoints were to evaluate the presence of a relationship between each patient's BMI and changes in these parameters. We also evaluated the relationship between urine protein excretion and the adiponectin concentration.
Statistics
The data are shown as the mean ± S.E. The Wilcoxon signed-rank test was performed to compare the changes in the parameters between before and after the study. Relationships between two parameters were evaluated using regres- sion analyses. Correlations were evaluated using the nonparametric method with Theil and Sen's regression analyses, and the regression coefficients were estimated with Kendall's tau. Repeated analysis of variance (ANOVA) was performed to compare changes in the metabolic parameters between the BMI>25 and BMI<25 groups. All analyses were performed using computer software (Kyprot 5.0, Kyence Lab Inc. Tokyo, Japan). A p value less than 0.05 was regarded as significant.
Results
Patient characteristics
Thirty-nine patients were entered into the study; however, 10 patients were excluded from the analysis because nine patients missed blood or urine sampling at a visit and one patient refused to continue the study for personal reasons. Termination of the study due to major adverse reactions did not occur in any of the patients. Therefore, data for the 29 patients who completed the study were evaluated.
The characteristics of the 29 patients at the initiation of the study are shown in Table 1 . Nineteen out of the 29 patients were diagnosed based on renal biopsies and the other 10 were diagnosed clinically. The mean blood pressure and BMI were 142/87 mmHg and 24.4, respectively. Moderate proteinuria was seen in all patients, and the mean urinary protein/creatinine ratio was 1,030 mg/g creatinine. Moderate renal dysfunction was also observed. The mean serum creatinine concentration and estimated GFR (eGFR) were 1.1 mg/dL and 51 mL/min/1.73 m 2 , respectively. Metabolic syndrome was diagnosed in three patients based on a large waist circumference, high blood pressure and dyslipidemia. The BMI was higher than 25 in all three patients. Histograms of BMI and the prescribed drugs are shown in Fig. 1 and Table 2 , respectively. Irbesartan was increased to 200 mg in 24 of the 29 patients. After the titration phase, four patients began taking Ca-antagonists and four patients increased the dose of the Ca-antagonist to maintain the target blood pressure level. Eight patients used statins in this study; however, the doses were not changed throughout the study period (Table 2) .
Changes in physical and blood/urine parameters after treatment
Blood pressure and the urinary protein/creatinine ratios significantly decreased after the study, while BMI did not change. The serum creatinine concentrations increased, and estimated GFR slightly but significantly decreased. Body weight and the serum potassium concentrations did not change significantly (Table 3 ). The adiponectin concentrations significantly increased, while the hsCRP and LDLcholesterol concentrations significantly decreased after the study. The mean concentrations of IL-6, TNF-a, insulin and leptin decreased, and the HDL-cholesterol concentrations increased; however, these changes were not statistically significant (p=0.07, 0.06, 0.07, 0.07 and 0.13, respectively, Table 3). Improvements in the insulin concentrations were significantly correlated with changes in the adiponectin concentrations (R=-0.53, p<0.01).
The relationships between BMI measured at the initiation of the study and the changes in the metabolic parameters are shown in Fig. 2 . There were moderate relationships between BMI and improvements in all of the metabolic parameters (R value with BMI=0.53, -0.43, -0.341, -0.43, -0.48 and -0.63; the p values for the nonparametric analysis were 0.01, 0.03, 0.03, 0.02, 0.02 and 0.01 for adiponectin, hsCRP, IL-6, TNF-a, leptin and insulin, respectively). There was a moderate relationship between improvements in the urinary protein/creatinine ratios and changes in the plasma adiponectin concentrations (Fig. 3, R=-0.44, p=0.02) ; however, the changes in the levels of urinary protein were not correlated with BMI or eGFR (R=-0.22, p=0.18 and R=0.20. p= 0.32, BMI and eGFR, respectively, data not shown). There were no significant correlations between the changes in eGFR and the changes in the adiponectin concentrations (R= 0.27, p=0.25, data not shown). No improvements in any of the metabolic parameters were found to be significantly correlated with changes in mean blood pressure (data not shown). Because we found these relationships, we further divided the patients into two groups using a threshold of BMI =25 and compared changes in the inflammatory parameters between the groups. The numbers of patients with a BMI>25 or a BMI<25 were 11 and 18, respectively. The basal characteristics, including age, gender and underlying disease, were not statistically different between the BMI>25 group and the BMI<25 group (data not shown). The changes in the adiponectin and hsCRP concentrations were significantly different between the two groups. The p values between the BMI<25 group and the BMI>25 group were 0.02 for adiponectin and 0.01 for hsCRP (Fig. 4) . Similar tendencies were also observed for IL-6, TNF-a, insulin and leptin (data not shown).
Discussion
The anti-proteinuric and renoprotective effects of irbesartan have been reported in prospective studies of patients with (13) and without (14) diabetes. It has also been reported that the mean reduction of diastolic blood pressure and proteinuria using 100 mg of the drug is 9 mmHg in patients with IgA nephropathy (14) , which is comparable with the results of the present study. We found that improvements in inflammatory cytokines caused by irbesartan treatment are correlated with BMI in patients with chronic glomerulonephritis. Only the concentrations of adiponectin and hsCRP significantly improved following treatment in all of the enrolled patients; however, improvements in other metabolic parameters were seen in the patients with a BMI>25. This is one of the most important finding of this study. Several groups have reported improvements in metabolic/inflammatory parameters induced by irbesartan treatment in hypertensive patients with diabetes (15, 16) or obesity (17) . In nondiabetic patients, irbesartan improves insulin sensitivity, although the IL-6 and TNF-a concentrations do not improve (5) . Despite the fact that we confirmed the absence of diabetes in our participants, we found that mild deterioration of these parameters from the basal point and improvements caused by irbesartan are correlated with BMI in glomerulonephritic patients. Therefore, the anti-metabolic effects of irbesartan were confirmed in nondiabetic patients with chronic glomerulonephritis, which is another important finding of this study. Because irbesartan possesses PPAR-g agonistic actions (18) , the effects observed in this study may represent such effects in vivo. We also found improvements in the LDL-cholesterol concentrations in this study, a finding that is similar to that reported in a previous study of patients with diabetes (15). We could not identify any reductions in body weight, as reported previously in diabetic pa- (16), which might be due to the different etiologies of the enrolled patients. No improvements in any of the metabolic parameters were found to be significantly correlated with changes in mean blood pressure in this study. Therefore, we believe that the effectiveness of irbesartan is independent at the cytokine level.
It has been reported that reduced adiponectin production directly deteriorates the podocyte function in glomeruli, thereby leading to albuminuria (19) , and may be one of the mechanisms of obesity-related glomerulopathy (8) . We observed particular improvements in the adiponectin concentrations in the higher BMI group in this study, which is in good agreement with the findings of a previous in vitro study that showed that ARBs with PPAR-g agonistic actions induce adiponectin production (20) . We also found a significant relationship between improvements in the adiponectin levels and reductions in proteinuria, which is important and comparable with the findings reported in a previous animal study (19) . According to the relationship between the levels of urine protein and adiponectin shown in Fig. 3 , reductions in the levels of urine protein were observed in all of the patients who showed increases in the levels of adiponectin, as well as in some of the patients whose adiponectin concentrations did not increase. This result may indicate that reductions in the levels of urinary protein can occur by two types of mechanisms: adiponectin/podocyte-dependent mechanisms (8) and adiponectin-independent mechanisms. The adiponectin-independent mechanisms may be explained by reductions in efferent artery resistance induced by the drug or improvements in other cytokines (such as IL-13). We could not confirm the presence of podocyte injury on renal biopsies in all patients. Indeed, some hypertensive nephropathy patients were also included. Further studies including patients with biopsy-proven obesity-related glomerulopathy should be carried out. We did not find any relationships between changes in eGFR and proteinuria in this study. Therefore, slight reductions in the renal function caused by the drug are not the reason for improvements in proteinuria.
There are several limitations associated with this study. The small number of participants and the relatively high rate of termination due to missing opportunities for blood/urine sampling may have affected the results. The mean blood pressure after treatment was approximately 131/81 mmHg, which was slightly higher than the target value. A singlearm study cannot exclude the possibility of a time effect on the results. It has also been reported that the PPAR agonistic action of ARBs varies with each drug, and the action of irbesartan is weaker than that of other ARBs such as telmisartan (12) . We selected irbesartan in this study because it is used in more than 80 countries and its affinity for renal tissue is higher than that of telmisartan (12) . Therefore, the anti-metabolic effects of irbesartan in glomerulonephritis patients without diabetes should be compared with those of other drugs in the future.
In summary, we found improvements in the concentrations of hsCRP and adiponectin following long-term treatment with irbesartan in patients with hypertensive chronic glomerulonephritis without diabetes. Although not statistically significant in all patients, improvements in several metabolic parameters, such as IL-6, TNF-a and leptin, were prominent in the high-BMI patients. Treatment with irbesartan is beneficial, especially in high-BMI patients.
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